Intravitreal Bevacizumab for Inflammatory Neovascular Membranes

• Status: Completed
• Trial end date: 2006-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Intravitreal injection of Bevacizumab in patients with Neovascular Membranes secondary to intraocular inflammation. We injected a single injection of Bevacizumab (2.5 mg/0.1 ml) and evaluate visual acuity , Fluorescein angiogram and retinal thickness by Optical Coherence Tomography (OCT) in 4 patients with Vogt Koyanagi Harada disease, 1 patient with Serpiginous Choroidopathy and 1 patient with Multifocal Choroiditis.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Asociación para Evitar la Ceguera en México
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• Clinical Diagnose

• Patient Consent

• Chronic stage of inflammation

Exclusion Criteria:

• only eye

• age lower than 30 yo.

• Systemic condition